ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells

References

• Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2010; 184:16-20; PMID:19857474; http://dx.doi.org/10.1016/j.cbi.2009.10.009
   PubMed Web of Science ®Google Scholar
• Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K, Edwards BK. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer 2000; 88:2398-424; PMID:10820364; http://dx.doi.org/10.1002/(SICI)1097-0142(20000515)88:10%3c2398::AID-CNCR26%3e3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334:1238-48; PMID:8606720; http://dx.doi.org/10.1056/NEJM199605093341906
   PubMed Web of Science ®Google Scholar
• Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356-61; http://dx.doi.org/10.4049/jimmunol.168.3.1356
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 2009; 127:145-54; PMID:19476510; http://dx.doi.org/10.1111/j.1365-2567.2009.03058.x
   PubMed Web of Science ®Google Scholar
• Crowder RN, El-Deiry WS. Caspase-8 regulation of TRAIL-mediated cell death. Exp Oncol 2012; 34:160-4; PMID:23070000
   PubMedGoogle Scholar
• Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005; 130:501-10; PMID:16098063; http://dx.doi.org/10.1111/j.1365-2141.2005.05656.x
   PubMed Web of Science ®Google Scholar
• Smith MA, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Kang MH, Reynolds CP, Maris JM, et al. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 54:307-10; PMID:19856388
   PubMed Web of Science ®Google Scholar
• Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22:8628-33; PMID:14634624; http://dx.doi.org/10.1038/sj.onc.1207232
   PubMed Web of Science ®Google Scholar
• Fox NL, Humphreys R, Luster TA, Klein J, Gallant G. Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. Expert Opin Biol Ther 2010; 10:1-18; PMID:19857186; http://dx.doi.org/10.1517/14712590903319656
   PubMed Web of Science ®Google Scholar
• Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Exp Opin Ther Targets 2010; 14:1091-108; PMID:20819019; http://dx.doi.org/10.1517/14728222.2010.519701
   PubMed Web of Science ®Google Scholar
• Daniel D, Yang B, Lawrence DA, Totpal K, Balter I, Lee WP, Gogineni A, Cole MJ, Yee SF, Ross S, et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007; 110:4037-46; PMID:17724141; http://dx.doi.org/10.1182/blood-2007-02-076075
   PubMed Web of Science ®Google Scholar
• Mouzakiti A, Packham G. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br J Haematol 2003; 122:61-9; PMID:12823346; http://dx.doi.org/10.1046/j.1365-2141.2003.04424.x
   PubMed Web of Science ®Google Scholar
• Hussain A, Doucet JP, Gutierrez M, Ahmad M, Al-Hussein K, Capello D, Gaidano G, Bhatia K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple pro-apoptotic proteins. Haematologica 2003; 88:167-75; PMID:12604406
   PubMed Web of Science ®Google Scholar
• Ucur E, Mattern J, Wenger T, Okouoyo S, Schroth A, Debatin KM, Herr I. Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells. Br J Cancer 2003; 89:2155-62; PMID:14647152; http://dx.doi.org/10.1038/sj.bjc.6601407
   PubMed Web of Science ®Google Scholar
• Gasparini C, Vecchi Brumatti L, Monasta L, Zauli G. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies. Curr Med Chem 2013; 20:2254-71; PMID:23458616; http://dx.doi.org/10.2174/0929867311320170009
   PubMed Web of Science ®Google Scholar
• Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13:1070-7; PMID:17767167; http://dx.doi.org/10.1038/nm1627
   PubMed Web of Science ®Google Scholar
• Stern HM, Padilla M, Wagner K, Amler L, Ashkenazi A. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin Cancer Res 2010; 16:1587-96; PMID:20179215; http://dx.doi.org/10.1158/1078-0432.CCR-09-3108
   PubMed Web of Science ®Google Scholar
• Travert M, Ame-Thomas P, Pangault C, Morizot A, Micheau O, Semana G, Lamy T, Fest T, Tarte K, Guillaudeux T. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl−xL. J Immunol 2008; 181:1001-11; http://dx.doi.org/10.4049/jimmunol.181.2.1001
   PubMed Web of Science ®Google Scholar
• Gallouet AS, Travert M, Bresson-Bepoldin L, Guilloton F, Pangault C, Caulet-Maugendre S, Lamy T, Tarte K, Guillaudeux T. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis. Clin Cancer Res 2014; 20:2663-73; PMID:24637636; http://dx.doi.org/10.1158/1078-0432.CCR-13-2305
   PubMed Web of Science ®Google Scholar
• Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol Cancer Ther 2012; 11:2087-95; PMID:22802267; http://dx.doi.org/10.1158/1535-7163.MCT-12-0366
   PubMed Web of Science ®Google Scholar
• Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 2013; 5:171ra17; PMID:23390247; http://dx.doi.org/10.1126/scitranslmed.3004828
   PubMed Web of Science ®Google Scholar
• Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAIL-dependent manner. Cancer Res 2015; 75(7):1423-32; http://dx.doi.org/10.1158/0008-5472.CAN-13-3451
   Web of Science ®Google Scholar
• Chargari C, Cosset JM. [The issue of low doses in radiation therapy and impact on radiation-induced secondary malignancies]. Bull Cancer 2013; 100:1333-42; PMID:24257106
   PubMed Web of Science ®Google Scholar
• Henry M, Savasan S. Controversies in the role of radiotherapy in the treatment of pediatric Hodgkin lymphoma. Ind J Pediatr 2013; 80:863-9; PMID:23975267; http://dx.doi.org/10.1007/s12098-013-1106-8
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004; 279:40044-52; PMID:15226295; http://dx.doi.org/10.1074/jbc.M404541200
   PubMed Web of Science ®Google Scholar
• Allen JE, Prabhu VV, Talekar M, van den Heuvel P, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and pharmacological screens converge in identifying FLIP, BCL2 and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anti-cancer agent ONC201/TIC10. Cancer Res 2015; 75(8):1668-74; http://dx.doi.org/10.1158/0008-5472.CAN-14-2356
   Web of Science ®Google Scholar
• Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001; 20:5595-610; PMID:11607812; http://dx.doi.org/10.1038/sj.onc.1204595
   PubMed Web of Science ®Google Scholar
• Klefstrom J, Verschuren EW, Evan G. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. J Biol Chem 2002; 277:43224-32; PMID:12202489; http://dx.doi.org/10.1074/jbc.M206967200
   PubMed Web of Science ®Google Scholar
• Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004; 24:8541-55; PMID:15367674; http://dx.doi.org/10.1128/MCB.24.19.8541-8555.2004
   PubMed Web of Science ®Google Scholar
• Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Devel 2000; 14:2501-14; PMID:11018017; http://dx.doi.org/10.1101/gad.836800
   PubMed Web of Science ®Google Scholar
• Ishizawa J, Kojima K, Chachad D, Ruvolo PP, Ruvolo VR, Jacamo R, Dilip A, Mu H, Zeng Z, Matre P, et al. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition. 2014
   Google Scholar
• Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget 2014; 5:12728-37; PMID:25587031
   PubMed Web of Science ®Google Scholar
• Rao J, Zhang RY, Chen Y, Chen GA, Xiao CJ. [Combined effect of TNF-related apoptosis induced ligand and Ara-C in inducing apoptosis of HL-60 cells and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Xhi 2008; 16:510-5
   PubMedGoogle Scholar